Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI (REC)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
40.1(c) 39.61(c) 39.67(c) 39.53(c) 39.71 Last
234 996 291 288 239 920 386 771 388 769 Volume
+0.78% -1.22% +0.15% -0.35% +0.46% Change
More quotes
Financials (€)
Sales 2017 1 301 M
EBIT 2017 402 M
Net income 2017 289 M
Debt 2017 331 M
Yield 2017 2,02%
Sales 2018 1 417 M
EBIT 2018 439 M
Net income 2018 314 M
Debt 2018 215 M
Yield 2018 2,21%
P/E ratio 2017 28,29
P/E ratio 2018 26,01
EV / Sales2017 6,64x
EV / Sales2018 6,01x
Capitalization 8 304 M
More Financials
Company
Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals.It operates through two segments: Pharmaceutical and Rare Diseases.The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Recordati
Trading Rating : Investor Rating :
More Ratings
Latest news on RECORDATI
07/27 RECORDATI : Very good results again in the first half 2017. continued growth in ..
07/27 RECORDATI : Very good results in the first half 2017. continued growth in sales ..
07/19 RECORDATI : The european commission approves reagila® (cariprazine) for the trea..
07/07 RECORDATI : Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosag..
07/03 RECORDATI : Acquisition of rights to astrazeneca's metoprolol based treatments i..
07/03 ASTRAZENECA : Completes agreement with recordati for seloken in europe
06/16 RECORDATI : Licenses an innovative treatment for neurotrophic keratitis
05/26 RECORDATI : Hogan Lovells Acts for Recordati on US$300 Million Acquisition of Co..
05/22 RECORDATI : ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS I..
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
More news
Sector news : Pharmaceuticals - NEC
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on RECORDATI 
RECORDATI SPA - 2016
A medium term support level to take advantage of
BUY
RECORDATI - 2014
Jump above 2-year old trend line
BUY
More Strategies
Latest Tweets
07/30Zacks Investment Research Downgrades Recordati $RCDTF to Hold  
07/30Zacks Investment Research Downgrades Recordati $RCDTF to Hold  
07/27RECORDATI: VERY GOOD RESULTS IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALE.. 
07/26Recordati downgraded by Zacks Investment Research to hold.  
07/19BRIEF-Recordati says Gedeon Richter was granted marketing authorization from .. 
More tweets
Qtime:23
News from SeekingAlpha
07/27 Recordati Industria Chimica e Farmaceutica reports 1H results
07/10 Strong Small Cap Performance Drives Second-Quarter Gains
05/22 WALL STREET BREAKFAST : Major Shakeup At Ford?
05/22 AstraZeneca sells Seloken for $300M
05/04 Recordati Industria Chimica e Farmaceutica reports Q1 results
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | REC | IT0003828271 | 4-Traders
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 36,6 €
Spread / Average Target -7,9%
EPS Revisions
Managers
NameTitle
Andrea Recordati Vice Chairman & Chief Executive Officer
Alberto Recordati Chairman
Fritz Squindo Chief Financial Officer, Executive Director & MD
Mario Garraffo Independent Non-Executive Director
Marco Vitale Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI47.36%9 785
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214